Results 41 to 50 of about 6,270 (167)

Retinal Capillary Density Reduction Contributes to Dysthyroid Optic Neuropathy via an L‐Arginine‐NO Pathway: A Metabonomics and Clinical Trial Study

MedComm, Volume 7, Issue 3, March 2026.
Oxidative stress induces endothelial nitric oxide synthase (eNOS) uncoupling and L‐arginine depletion, reducing nitric oxide (NO) bioavailability in vascular endothelium and contributing to decreased retinal capillary density (RCD) in dysthyroid optic neuropathy (DON).
Yunhai Tu, Congcong Yan, Lu Chen, Weijie Liu, Xiaozhou Hu, Mengyuan Gao, Wei Rao, Jiayi Zhang, Junye Zhu, Hui Wu, Kang Zhang, Meng Zhou, Wencan Wu   +12 more
wiley   +1 more source

Management of Graves' ophthalmopathy

, 2007
Management of Graves' ophthalmopathy is preferably done in a multidisciplinary setting. Smoking is associated with worse disease outcome. (131)I therapy for hyperthyroidism can also worsen ophthalmopathy, especially if administered during active disease ...
Wiersinga, Wilmar M.
core   +1 more source

The Diagnostic Value of Mean Apparent Propagator‐MRI in Dysthyroid Optic Neuropathy: A Quantitative Analysis of the Entire Visual Pathway

CNS Neuroscience &Therapeutics, Volume 32, Issue 2, February 2026.
The diagnostic model combining orbital and intracranial MAP‐MRI parameters could significantly optimize diagnostic efficiency of dysthyroid optic neuropathy. Comprehensive MAP‐MRI parameters analysis of the entire visual pathway enables a deeper understanding of disease involvement, provides novel insights into the early accurate diagnosis and ...
Mengsha Zou, Dide Wu, Yanglei Cheng, Haodong Qin, Zhiyun Yang, Shubin Hong, Hongzhang Zhu, Cui Yan   +7 more
wiley   +1 more source

Blepharoplasty in Graves’ Ophthalmopathy

, 2017
Graves’ ophthalmopathy (GO) is the main extrathyroidal manifestation of Graves’ disease. Many patients require rehabilitative surgery, such as orbital decompression and lipectomy, to restore function and appearance.
Umberto Zanetti, Andrea Castellani, Gabriele Bocchialini   +2 more
core   +1 more source

Evaluation of Galectin-3 in Graves’ Disease With and Without Ophthalmopathy

Endocrinology Research and Practice, 2023
Objective: There is a link between thyroid-associated ophthalmopathy and Graves’ disease; however, the exact pathophysiological mechanism remains unclear.
Muhammed Akın, Hüseyin Karaaslan, Mehmet Ali Eren, İsmail Koyuncu, Tevfik Sabuncu   +4 more
doaj  

Teprotumumab for Thyroid Eye Disease: Efficacy and Impact on Orbital Decompression Utilization

Laryngoscope Investigative Otolaryngology, Volume 11, Issue 1, February 2026.
Teprotumumab has been proven effective in thyroid eye disease and associated exophthalmos management. Since its FDA approval in 2020, teprotumumab therapy has been a popular choice for managing exophthalmos which has resulted in decreased utilization of orbital decompression surgery, from 36.8% between 2015 and 2020 to 11.1% TED patients between 2020 ...
Nitish Kumar, Pedro Lança Gomes, Gaurav Jategaonkar, Michael J. Marino, Amar Miglani, Devyani Lal   +5 more
wiley   +1 more source

Exploring tear fluid biomarkers and the ocular surface in thyroid eye disease

Acta Ophthalmologica, Volume 104, Issue 1, Page e28-e38, February 2026.
Abstract Purpose To examine ocular surface changes and inflammatory tear fluid biomarkers in patients with thyroid eye disease (TED). Methods We included 106 Graves' disease (GD) patients (36 without TED, 32 with active and 38 with inactive TED) and 106 age‐ and sex‐matched healthy subjects for ophthalmological evaluation, including ocular surface ...
Mikael Thomassen Neset, Roy Miodini Nilsen, Kristian Løvås, Kathrine Halsøy, Håkon Reikvam, Ann‐Elin Meling Stokland, Grethe Åstrøm Ueland, Anette S. B. Wolff, Hans Christian D. Aass, Sjur Reppe, Eystein Sverre Husebye, Eyvind Rødahl, Tor Paaske Utheim, Hans Olav Ueland   +13 more
wiley   +1 more source

Rare concurrent ocular myasthenia gravis and Graves’ ophthalmopathy in a man with Poland syndrome: a case report

BMC Neurology, 2020
Background Ocular myasthenia gravis and Graves’ ophthalmopathy are autoimmune diseases that are mediated by membrane receptors and share many identical clinical processes.
Jingqun Tang, Chao Qin
doaj   +1 more source

TSHR‐Targeting Nucleic Acid Aptamer Treats Graves' Ophthalmopathy via Novel Allosteric Inhibition (Adv. Sci. 4/2026)

Advanced Science, Volume 13, Issue 4, 19 January 2026.
An Allosteric Strategy for Thyroid Eye Disease This illustration depicts an aptamer (purple) binding to the target protein (white) at an allosteric site. This strategic binding induces a conformational change that acts as a shield, preventing pathogenic autoantibodies (red) from initiating the disease cascade, while leaving the protein's normal ...
Yanchen Zhang, Ende Wu, Weibin Liu, Ling Zeng, Neng Ling, Hongmei Wang, Zhixing Li, Shuang Yao, Tonghe Pan, Xuanwen Li, Yate Huang, Xiaojing Li, Yunhai Tu, Wentao Yan, Jianzhang Wu, Mao Ye, Wencan Wu   +16 more
wiley   +1 more source

Clinical and Radiological Findings in Patients with Newly Diagnosed Graves’ Ophthalmopathy

International Journal of Endocrinology, 2021
Background. Graves’ ophthalmopathy is the most common extrathyroidal manifestation of Graves’ disease. The objective of this study was to investigate the clinical ophthalmological and MRI findings in newly diagnosed Graves’ ophthalmopathy. Methods.
Yakup Cevik, Hande Taylan Sekeroglu, Burce Ozgen, Kadriye Erkan Turan, Ali Sefik Sanac   +4 more
doaj   +1 more source